このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)

2026年11月10日 更新者:University Hospital, Tours

Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial

The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:

  • Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
  • What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.

Participants will be randomized to one of two treatment strategies:

  • Experimental group: Surgical excision of the labial venous malformation (VM).
  • Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.

Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.

Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.

Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

50

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Paris、フランス
        • Lariboisière
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Annouk BISDORFF, MD
      • Paris、フランス
        • Necker
        • コンタクト:
        • 主任研究者:
          • Olivia BOCCARA, MD
      • Tours、フランス
        • CHRU de Tours
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Aline JOLY, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

4年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 4 years
  • Symptomatic venous malformation of the lower and/or upper lip
  • Venous pocket with an area of between 10 and 50 mm²
  • No history of surgery or interventional radiology in the area within the two years prior to inclusion
  • Suitable for sclerotherapy and surgery
  • Patient covered by the National Health Service
  • Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Women of childbearing age not using effective contraception throughout the study
  • Patients under guardianship or curatorship, or subject to a court-ordered protective measure
  • Other vascular abnormalities
  • Contraindications to MRI
  • Contraindications to Aetoxisclerol®
  • Contraindications to general anaesthesia
  • Contraindications to surgery

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Surgical strategy

Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects.

The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis.

アクティブコンパレータ:Sclerotherapy strategy

Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol).

The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops.

Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Global change
時間枠:From enrollment to Month 12 post intervention

Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint).

From enrollment to Month 12 post intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Aesthetic impact of the venous malformation
時間枠:Month 0 and Month 12

Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention.

Month 0 and Month 12
Functional impact: overall mouth function
時間枠:Month 0 and Month 12

Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome

Month 0 and Month 12
Functional impact: lip continence
時間枠:Month 0 and Month 12

Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome

Month 0 and Month 12
Functional impact: speech intelligibility
時間枠:Month 0 and Month 12

Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome

Month 0 and Month 12
Overall patient satisfaction: Likert scale
時間枠:From enrollment to Month 12

Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome

From enrollment to Month 12
Overall patient satisfaction: Goal Attainment Scale
時間枠:Month 12

Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005).

Month 12
Number of painful days: Total number of painful days
時間枠:The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)

Total number of painful days assessed using either a patient diary or the online ePRO portal.

The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
Number of painful days: Number of painful days with a VAS pain score > 3/10
時間枠:The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)

Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal.

The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
Venous Malformation volume on MRI
時間枠:Month 0 and Month 12

Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation.

Month 0 and Month 12
Coagulation: D-dimer
時間枠:Month 12

D-dimer

Month 12
Coagulation: fibrinogen level
時間枠:Month 12

Fibrinogen level

Month 12
Adverse events including complications
時間枠:From enrollment to Month 12

Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal

From enrollment to Month 12
Acceptability of the interventions
時間枠:Month 1, Month 3 , and Month 12

Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome

Month 1, Month 3 , and Month 12
Healthcare costs
時間枠:From enrollment to Month 12 following the intervention

In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system.

From enrollment to Month 12 following the intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2028年7月1日

研究の完了 (推定)

2030年1月1日

試験登録日

最初に提出

2026年9月15日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • DR240317
  • 2025 (米国 NIH グラント/契約)
  • 2025-521374-34-00 (Ctis)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。